Cargando…

Clinical Outcomes of Switching to Insulin Glargine 300 U/ml from Other Basal Insulins in People with Type 2 Diabetes in Italy: A Real-World Study

INTRODUCTION: Primary aim was to provide real-world evidence of the outcomes after the switch to glargine 300 U/ml (Gla-300) from other basal insulins (first or second generation) in Italy. METHODS: Multicenter, observational, retrospective study based on electronic medical records. RESULTS: Overall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ragonese, Mauro, Larosa, Monica, Angotti, Stefania, Annese, Stefania, Cruciani, Laura, Dainelli, Michela, Lucisano, Giuseppe, Prosperini, Giuseppe, Sacco, Michele, Salomone, Enrica, Saponara, Caterina, Semprini, Roberta, Rossi, Maria Chiara, Nicolucci, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509008/ https://www.ncbi.nlm.nih.gov/pubmed/32813262 http://dx.doi.org/10.1007/s13300-020-00902-1

Ejemplares similares

Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study
por: Laviola, Luigi, et al.
Publicado: (2020)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL
por: Lindauer, Klaus, et al.
Publicado: (2019)

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Buscemi, Silvio, et al.
Publicado: (2019)

Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL
por: Yu, Neng Chun
Publicado: (2019)

Comparative effectiveness and safety of glargine 300 U/mL versus degludec 100 U/mL in insulin-naïve patients with type 2 diabetes. A multicenter retrospective real-world study (RESTORE-2 NAIVE STUDY)
por: Fadini, Gian Paolo, et al.
Publicado: (2022)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
por: Lau, Ip Tim, et al.
Publicado: (2017)

Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Yamabe, Mizuho
Publicado: (2019)

Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
por: Kovatchev, Boris, et al.
Publicado: (2020)

Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of Diabetes
por: White, John R.
Publicado: (2016)

Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
por: Gourdy, Pierre, et al.
Publicado: (2019)

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml
por: Becker, R H A, et al.
Publicado: (2015)

Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives
por: de Galan, Bastiaan E
Publicado: (2016)

Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes
por: Maffeis, Claudio, et al.
Publicado: (2022)

Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
por: Miller, Michelle, et al.
Publicado: (2021)

In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes
por: Schiavon, Michele, et al.
Publicado: (2020)

Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study
por: Takeishi, Soichi, et al.
Publicado: (2017)

Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin‐naïve people with type 2 diabetes: The EDITION AP randomized controlled trial
por: Ji, Linong, et al.
Publicado: (2019)

Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes
por: Pohlmeier, Harald, et al.
Publicado: (2017)

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
por: Bolli, Geremia B., et al.
Publicado: (2021)

A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes
por: Tibaldi, Joseph, et al.
Publicado: (2019)

Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
por: Müller-Wieland, Dirk, et al.
Publicado: (2023)

Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice‐daily basal insulin to once‐daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis)
por: Roussel, Ronan, et al.
Publicado: (2017)

A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study
por: Ito, Hiroyuki, et al.
Publicado: (2018)

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
por: Bolli, G B, et al.
Publicado: (2015)

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)
por: Matsuhisa, M., et al.
Publicado: (2016)

Controlling glycemic variability in people living with type 1 diabetes receiving insulin glargine 300 U/mL (Gla-300)
por: Mader, Julia K, et al.
Publicado: (2022)

Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross‐over study
por: Yamabe, Mizuho, et al.
Publicado: (2018)

Comment on “a comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes”
por: Freemantle, Nick, et al.
Publicado: (2019)

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study
por: Galstyan, Gagik R., et al.
Publicado: (2022)

Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial
por: Danne, Thomas, et al.
Publicado: (2020)

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension
por: Yki‐Järvinen, H., et al.
Publicado: (2015)

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
por: Edelman, Steven, et al.
Publicado: (2023)

Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs
por: Werner, Ulrich, et al.
Publicado: (2020)

Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies
por: Harris, Stewart B., et al.
Publicado: (2022)

Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures
por: Lingvay, Ildiko, et al.
Publicado: (2017)

Real‐world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin
por: Zhou, Fang Liz, et al.
Publicado: (2018)

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)
por: Terauchi, Y., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8748q8t4gttgeeo1kngao9o9mi